Luminary Therapeutics develops allogeneic cell therapies using its Gamma 2.0+ platform to target solid tumors and B cell malignancies, addressing challenges such as antigen escape and limited tumor infiltration. The company aims to reduce relapse rates and manufacturing costs, providing more effective treatment options for underserved patient populations.
Funding
$13.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SFounders
Product
Problem
Existing CAR-T cell therapies face challenges including antigen escape, limited tumor infiltration, high manufacturing costs, and long lead times, which can delay treatment and contribute to high relapse rates, especially in solid tumors and B-cell malignancies.
Solution
Luminary Therapeutics develops allogeneic cell therapies using its Gamma 2.0+ platform to overcome key limitations of current CAR-T therapies. The platform is designed to enhance persistence and durability while reducing manufacturing costs. Luminary's approach includes a Dual CAR architecture to target multiple cancer antigens, optimized costimulatory domain arrangements to prevent T cell exhaustion, and the use of the TcBuster transposon system for large genetic cargo capacity, enabling the inclusion of cytokine sinks to neutralize immunosuppressive signals in the tumor microenvironment. This multifaceted approach aims to improve treatment efficacy, reduce relapse rates, and provide more accessible cell therapies for both hematological malignancies and solid tumors. The BAFF Ligand Based CAR program specifically addresses antigen escape, a major cause of relapse.
Target Audience
The primary target audience includes patients with solid tumors and B-cell malignancies who are underserved by existing CAR-T cell therapies, as well as the clinicians who treat them.
Features
- Allogeneic Gamma 2.0+ platform designed for enhanced persistence and durability
- Split Co-Stim Dual CAR approach targeting multiple cancer antigens in solid tumors
- Optimized costimulatory domain arrangement to prevent T cell exhaustion
- TcBuster transposon system for large genetic cargo capacity, enabling inclusion of cytokine sinks
- BAFF Ligand Based CAR program to address antigen escape in B-cell malignancies
- Manufacturing processes designed to reduce costs and lead times